Ultime notizie per Apyx Medical (NASDAQ:APYX) Azioni

Apyx Medical

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Bovie Medical

Apyx Medical Corp

WIIM

VRRM

Verra Mobility shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 revenue guidance below estimates. Also, Barid and Deutsche Bank lowered their respective price targets on the stock.

ONTO

Onto Innovation shares are trading lower after Needham cut its price target on the stock from $245 to $230.

Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) decision to shut down Arkane Austin, the studio behind acclaimed titles like Redfall and Prey, has faced blunt criticism from industry veteran and Arkane founder Raphaël Colantonio. 
Colantonio, now leading WolfEye Studios, described the decision <a href="https://www.pcgamer.com/games/microsoft-closing-arkane-austin-was-a-dumb-move-says-founder-and-former-president/">to</a> PC Gamer as "stupid" and "not a good decision."
<h3 class="wp-block-heading">A &#8216;Special Group&#8217; Cut In A Corporate Reshuffle</h3>
Reflecting on the closure, Colantonio said: "I think if you look a little bit, it&#8217;s obvious that Arkane Austin was a very special group of people that have made some cool things and that could pull it off again." 
See Also: <a href="https://www.benzinga.com/general/gaming/24/06/39417676/microsoft-issues-redfall-hero-pass-dlc-refunds-after-arkane-austin-closure">Microsoft Issues Redfall Hero Pass DLC Refunds After Arkane Austin Closure</a>
He added: "I think it was a decision that just came down to, &#8216;We need to cut something.&#8217; Was it to please the investors, the stock market? They&#8217;re playing a different game."
The closure of Arkane Austin, alongside studios like Tango Gameworks and Alpha Dog Games, formed part of a broader reorganization within Microsoft, which had announced plans to reduce its gaming division workforce by 1,900 employees. 
In a memo, Xbox Game Studios head Matt Booty cited "reprioritization of titles and resources" as the driving force behind the cuts. 
While Microsoft&#8217;s CEO Satya Nadella received a notable pay raise to $30 million last year, the company continues to grapple with evolving industry demands and cost pressures.
<h3 class="wp-block-heading">Irreplaceable Talent And The Challenge Of Rebuilding</h3>
Colantonio doubted whether the unique chemistry at Arkane Austin could ever be replicated. He pointed to key team members like Harvey Smith and Ricardo Bare, whose collaboration played a huge role in the studio&#8217;s achievements. 
"When you have that magic of Harvey and Ricardo etc. that all come together, it&#8217;s a specific moment in time and space that just worked out this way, that took forever to reach,&#8221; he said. &#8220;Those people together can really make magic."
"It's not like, &#8216;Doesn&#8217;t matter, we&#8217;ll just rehire.&#8217; No, try it. That's what big groups do all the time. They try to just hire massively and overpay people to create those magic groups. It doesn't work like this. So to me, that was stupid. But what do I know?"
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/06/39534876/bethesda-game-studios-montreal-announces-unionization-plans">Bethesda Game Studios Montreal Announces Unionization Plans</a></li>
</ul>
Image credits: Shutterstock.

Gaming

News

General

MSFT

Microsoft's Decision To Shut Down Arkane Austin Called 'Stupid' By Studio Founder

MDGL

Madrigal Pharmaceuticals shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $411 to $441.

MDU Resources shares are trading lower. Everus Construction Group completed its spinoff from the company.

Benchmark analyst Josh Sullivan maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $150 to $300.

Price Target

Analyst Ratings

FTAI

Benchmark Maintains Buy on FTAI Aviation, Raises Price Target to $300

ARES

Ares Management shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Church & Dwight shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance.

<ul>
<li>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</li>
<li>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</li>
<li>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</li>
</ul>
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Biotech

TEVA

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

MBLY

Mobileye Global shares are trading higher after Baird and TD Cowen raised their respective price targets on the stock.

Investment firm 21Shares submitted a request to the U.S. Securities and Exchange Commission (SEC) for approval to launch a spot XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">exchange-traded fund (ETF)</a>.
What Happened: 21Shares <a href="https://www.sec.gov/Archives/edgar/data/2028835/000121390024093305/ea0219336-01.htm">filed</a> an S-1 registration statement with the SEC on Friday proposing a fund, named the 21Shares Core XRP Trust to be listed on the Cboe BZX Exchange. Coinbase Custody Trust Company is expected to serve as the fund&#8217;s custodian.
This move is part of 21Shares&#8217; ongoing efforts to expand U.S. investor access to the cryptocurrency asset class. The firm joins a growing list of companies competing for different crypto ETFs, following the SEC&#8217;s initial approval of crypto ETFs earlier this year.
The Block <a href="https://www.theblock.co/post/324186/21shares-looks-to-secure-sec-approval-for-xrp-etf-amid-growing-interest-in-other-crypto-funds?utm_source=rss&amp;utm_medium=rss">reported</a> that Canary Capital and Bitwise are among the other firms applying for a spot XRP ETF despite possible challenges.
The SEC has previously been <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41157465/gary-genslers-sec-appeals-2023-ruling-against-ripple-labs-xrp-tanks-10-just-prolongs-compl">involved in a legal dispute with Ripple</a>, accusing the company of raising $1.3 billion through the sale of XRP, which it considers an unregistered security. The case between Ripple and the SEC is still ongoing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">BlackRock&#8217;s Bitcoin ETF Crosses 1 Million BTC In Assets Under Management</a>
Why It Matters: The recent move by 21Shares to seek approval for an XRP ETF indicates a growing trend among investment firms to broaden investor access to the cryptocurrency market through ETFs.
This development comes in the wake of increased interest in cryptocurrency ETFs. In July 2024, Cboe Global Markets Inc. had submitted a request to the SEC to list Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) spot exchange-traded funds applied by VanEck and 21Shares. If approved, these would be the <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39679535/solana-jumps-5-5-as-cboe-files-application-with-sec-to-list-vaneck-21shares-spot-etfs">first ETF products linked to Solana.</a>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41584575/bitcoin-etfs-vs-ethereum-etfs-why-does-eth-keep-underperforming">Bitcoin ETFs Vs Ethereum ETFs: Why Does ETH Keep Underperforming?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

$XRP

XRP ETF Coming Soon? 21Shares Files For One Despite Ripple's Legal Battles

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE – Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Nov. 1:
Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) saw increased interest from investors during the week, which comes ahead of several potential catalysts. The life sciences and diagnostics company is set to report fourth-quarter financial results on Nov. 25 and host an analyst day on Dec. 17. Recent <a href="https://www.benzinga.com/quote/A/analyst-ratings">analyst activity</a> on the stock saw Barclays maintain an Underweight rating while raising the price target from $135 to $145. Evercore ISI maintains an In-Line rating while raising the price target from $135 to $145. The stock was up over 3% in the last five trading days as shown on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below. It remains down around 2% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="462" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png" alt="" class="wp-image-626124" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-300x138.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-768x354.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) saw increased interest from investors ahead of third-quarter financial results, which are set for Nov. 7. Analysts expect the company to report earnings per share of 39 cents and revenue of $619.8 million, compared to earnings of 33 cents per share and revenue of $493.3 million in last year's third quarter. Trade Desk has beaten earnings per share estimates in seven of the last eight quarters and beaten revenue estimates from analysts in more than 10 straight quarters.
Wedbush analyst Daniel Ives <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41144914/meta-trade-desk-amazon-digital-ad-titans-set-for-strong-2025-growth-tech-analyst-sa">recently highlighted </a>the growth potential for Trade Desk in the third quarter.
&#8220;Our survey showed accelerating growth for TTD in 3Q versus 2Q,&#8221; Ives said.
Trade Desk's <a href="https://www.benzinga.com/news/earnings/24/08/40267737/the-trade-desk-stock-climbs-after-better-than-expected-q2-results">second-quarter results</a> saw a customer retention rate of over 95%, continuing a 10-year streak. With potential strong growth and AI initiatives being integrated, the stock could generate some buzz with its third-quarter results.
The stock was down slightly over the last five days, but is up around 70% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png" alt="" class="wp-image-626125" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) made the list for the first time. The Stock Whisper Index typically highlights only stocks and leaves the ETFs out. But each week, ETFs like the SPY, QQQ and sometimes other well-known ETFs see rising interest based on volatility. Schwab tracks the Dow Jones U.S. Dividend 100 Index. It offers investors exposure to some of the largest U.S. companies that pay dividends and have a strong track record of paying out dividends. Top holdings in the ETF include Bristol Myers Squibb, Blackrock, Cisco Systems, Home Depot and Chevron.
With rising global tensions, macroeconomic uncertainties and the 2024 presidential election leaving some investors on edge, the ETF could be seeing increased interest thanks to its dividend income and positions in blue chip companies.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png" alt="" class="wp-image-626126" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-768x394.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Reinsurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>): The life and health reinsurance company saw increased interest over the week likely due to quarterly financial <a href="https://investor.rgare.com/news-releases/news-release-details/reinsurance-group-america-reports-record-third-quarter-results">results</a>. The company reported third-quarter earnings per share of $6.13 and revenue of $5.65 billion, beating Street consensus estimates according to Benzinga Pro. Reinsurance Group's third quarter had record financial results. The strong quarter could put the stock on investors radar for future growth opportunities.
Shares of the reinsurance company were up around 2% for the last five days and are up over 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png" alt="" class="wp-image-626127" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is scheduled to report third-quarter financial results on Nov. 6. The company is behind the PreTRM test for pregnancy preterm testing. An investor presentation highlighted the company's future product pipeline to include a predictive analytics product and a time-to-birth test. Shares of the pregnancy diagnostics company were up 16% over the last five trading days.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png" alt="" class="wp-image-626128" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 4</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/10/41296909/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 11</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 25</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet</a></li>
</ul>

Exclusives

Trading Ideas

SCHD

SERA

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

MSTR

MicroStrategy shares are trading lower. The company may be moving on continued weakness after reporting worse-than-expected Q3 financial results on Wednesday.

Zions Bancorporation, N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) announced today that its board of directors ("board") declared a regular quarterly dividend of $0.43 per common share, payable November 21, 2024, to shareholders of record at the close of business on November 14, 2024.

Dividends

ZION

Zions Bancorporation Increases Quarterly Dividend From $0.41 To $0.43 Per Share

Shares of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are trading lower Friday. Here&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41683531/michael-saylor-calls-microstrategy-the-public-equity-play-on-bitcoin-maximalism-heres-whos">what you need to know.</a>
What To Know: On Wednesday, MicroStrategy reported third-quarter earnings with quarterly losses of $1.56 per share which missed the analyst consensus estimate of 14 cents, and quarterly sales of $116.071 million which missed the analyst consensus estimate of $122.66 million by 5.37 percent. This is a 10.34 percent decrease over sales of $129.462 million the same period last year.
The company also recently announced a further deepening of its Bitcoin-focused treasury strategy, expanding its holdings to 252,220 BTC, now valued at approximately $18.23 billion. CEO Michael Saylor highlighted MicroStrategy's role as a "public equity play on Bitcoin maximalism," reinforcing the company's plan to raise an <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41676449/michael-saylor-the-egg-man-peter-schiff-points-out-a-potential-pitfall-of-microstategys-42">additional $42 billion in equity</a> and debt over the next three years to finance Bitcoin acquisitions.
MicroStrategy achieved a 17.8% BTC yield, outpacing traditional benchmarks like the S&amp;P 500 and reporting an 825% return on Bitcoin investments since pivoting its treasury in 2020. However, this strategy has contributed to a widened net loss, reaching $340 million, compared to $143.4 million in the same period last year.
Analyst Ratings: Benchmark, TD Cowen, Maxim Group and Canaccord Genuity all maintained "Buy" ratings on MicroStrategy, with price targets raised to $300. MicroStrategy&#8217;s move has also encouraged other companies like Cathedra Bitcoin and Metaplanet to adopt similar strategies, underscoring its influence in corporate digital asset adoption.
MSTR Price Action: MicroStrategy shares were down 6.93% at $235.38 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01142904/MSTR-1024x537.png" alt="" class="wp-image-626117" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01142904/MSTR-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01142904/MSTR-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01142904/MSTR-768x403.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01142904/MSTR.png 1453w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41692969/bristol-myers-squibb-expects-new-schizophrenia-treatment-to-boost-long-term-growth-">Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious</a></li>
</ul>
Image Via Shutterstock.

Movers

MicroStrategy Shares Are Falling Today: What You Need To Know

Theriva Biologics, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock is trading higher after the company announced it was selected as a finalist for Merck&#8217;s KGaA&#8217;s EMEA <a href="https://www.benzinga.com//node/41686461">Advance Biotech Grant.</a>
What To Know: Finalists for the grant will present their projects to a six-judge panel from Merck&#8217;s Emerging Biotech group at BIO Europe 2024 in Stockholm, Sweden.
Theriva, specifically General Director of EU Subsidiary Manel Cascalló, will provide an overview of VCN-01, which is currently undergoing a Phase 2b clinical trial for first-line metastatic pancreatic cancer in conjunction with standard chemotherapy. The presentation is scheduled for Nov. 4. 
Winners receive financial support and&nbsp;guidance&nbsp;on navigating the path to commercialization, including consultation with M Ventures.
How To Buy Theriva Biologics Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Theriva Biologics's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41681685/intel-shares-surge-in-premarket-after-q3-results-whats-going-on">Intel Shares Surge In Premarket After Q3 Results: What&#8217;s Going On</a>
TOVX Price Action: At the time of writing, Theriva shares are trading 31.6% higher at $1.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Unsplash/ Volodymyr Hryshchenko

TOVX

What's Going On With Theriva Biologics Stock Friday?

Bernstein analyst Mark Shmulik maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $225 to $235.

AMZN

Bernstein Maintains Outperform on Amazon.com, Raises Price Target to $235

Guidance

Avis Budget Said 'Nothing Below $1B Of Adjusted EBITDA Acceptable' This Year

Bernstein analyst Aneesha Sherman maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Market Perform and raises the price target from $4.25 to $6.5.

PTON

Bernstein Maintains Market Perform on Peloton Interactive, Raises Price Target to $6.5

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Apyx Medical (APYX – Research Report) today. The company's shares closed yesterday at $...

Craig-Hallum Sticks to Its Buy Rating for Apyx Medical (APYX)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Apyx Medical (APYX – Research Report). The company's shares cl...

Apyx Medical GAAP EPS of -$0.19 beats by $0.01, revenue of $12.14M beats by $0.39M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Apyx Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/apyx-stock-quote/">APYX</a>) just reported results for the second quarter of 2024.<ul><li>Apyx Medical reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $12.15 million.</li><li>This was 3.40% better than the analyst estimate for revenue of $11.75 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/apyx-stock-earnings-apyx-medical-for-q2-of-2024/">APYX Stock Earnings: Apyx Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

APYX Stock Earnings: Apyx Medical Beats EPS, Beats Revenue for Q2 2024

Apyx Medical (APYX) Receives a Hold from Piper Sandler

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Apyx Medical (APYX – Research Report), with a price target o...

Lake Street Sticks to Its Buy Rating for Apyx Medical (APYX)

Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Apyx Medical (APYX – Research Report). The company's shar...

JMP Securities Sticks to Their Hold Rating for Apyx Medical (APYX)

Apyx Medical (APYX) Gets a Buy from Craig-Hallum

InMode: A Deep Dive After Q3 Earnings

AIRS

APYX

CUTR

INMD

RVNC

Press Releases

Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Apyx Medical Corporation Announces Board Leadership Transition

Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook

Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

Renuvion Named #1 Trusted Body Contouring Technology by Doctors*

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Comments

Apyx Medical

Notizie

Ultime notizie per Apyx Medical (NASDAQ:APYX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO